ROIV - Roivant Sciences Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$36.17
DETAILS
HIGH:
$42.00
LOW:
$30.00
MEDIAN:
$37.00
CONSENSUS:
$36.17
UPSIDE:
20.73%
About Roivant Sciences Ltd. (https://roivant.com)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Mayukh Sukhatme | President, Chief Investment Officer & Director | 1976 | $81,640,782 USD |
| Eric Venker | President & Chief Executive Officer of Immunovant | 1987 | $6,671,119 USD |
| Matthew Gline | Chief Executive Officer & Director | 1984 | $5,715,893 USD |
| Richard Pulik | Chief Financial Officer | 1980 | $1,553,179 USD |
| Jennifer Humes | Chief Accounting Officer | 1982 | $324,640 USD |
| Alex Gasner | Executive Vice President of Roivant Health | – | – |
| Frank Torti | President & Vant Chair | 1979 | – |
| Huafeng Xu | Chief Technology Officer | – | – |
| Ian Rosenblum | Chief Information Officer | – | – |
| Josh Chen | General Counsel | – | – |
| Kelly Graff | Head of People | – | – |